Pliant Therapeutics to Participate in Upcoming Investor Events
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a biotechnology firm focused on fibrosis therapies, announces participation in key investor events in March 2023. Leadership, including President Bernard Coulie, will engage in fireside chats at the Cowen 43rd Annual Health Care Conference on March 8 and the Oppenheimer 33rd Annual Healthcare Conference on March 13. An invitation-only meeting with investors will also occur on March 23 as part of the Citi West Coast Biotech Bus Trip. Pliant's lead candidate, bexotegrast, aimed at treating idiopathic pulmonary fibrosis and primary sclerosing cholangitis, has received multiple FDA designations, with Phase 2a trials underway.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced senior management’s participation at the following investor events in March:
- Cowen 43rd Annual Health Care Conference Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, and Éric Lefebvre, M.D., Pliant’s Chief Medical Officer, will participate in a fireside chat on Wednesday, March 8, 2023, at 1:30 p.m. ET.
- Oppenheimer 33rd Annual Healthcare Conference Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, and Éric Lefebvre, M.D., Pliant’s Chief Medical Officer, will participate in a virtual fireside chat on Monday, March 13, 2023, at 2:40 p.m. ET.
- Citi West Coast Biotech Bus Trip Members of Pliant’s senior management will meet with investors on Thursday, March 23, 2023, as part of an invitation-only event hosted by Citi.
Interested parties can access the Cowen and Oppenheimer fireside chats from the Investor Relations’ Events & Presentation page of Pliant’s website with an audio archive available for 30 days from the time it is made available.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral small molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant is currently conducting Phase 2a trials of bexotegrast in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis. Pliant is initiating a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition to clinical stage programs, Pliant currently has a preclinical program targeting muscular dystrophies. For additional information about Pliant Therapeutics, visit www.PliantRx.com and follow us on Twitter, LinkedIn, Facebook and YouTube.
Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
IR@Pliantrx.com
FAQ
What investor events is PLRX participating in March 2023?
Who will represent PLRX at the March investor events?
What is the lead product candidate for Pliant Therapeutics (PLRX)?
What designations has PLRX received for bexotegrast?
What is the current status of bexotegrast trials by PLRX?
